Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

• Status: Active, not recruiting
• Trial end date: 2024-02-28

Summary

This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks with a quality of life assessment for 40 additional weeks in patients with operable HER2+/HR+ breast cancer.

• Phase: Phase 2

Details

• Lead Sponsor: Palleos Healthcare GmbH
• Collaborators: CANKADO; Cankado Service GmbH; Roche Pharma AG; WSG WOMEN´S HEALTHCARE STUDY GROUP
• Treatments: Albumin-Bound Paclitaxel; Anastrozole; Aromatase Inhibitors; Cyclophosphamide; Epirubicin; Exemestane; Goserelin; Letrozole; Leuprolide; Paclitaxel; Pertuzumab; Tamoxifen; Taxane; Trastuzumab